Nature Reviews Gastroenterology & Hepatology· 2021Q1· Review

Advances in immunotherapy for hepatocellular carcinoma

Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, Ignacio Melero

1,362citations
Q1SCImago
2021year

Short summary

The combination of atezolizumab (anti-PDL1) and bevacizumab (anti-VEGF) is becoming the standard first-line therapy for hepatocellular carcinoma (HCC), showing strong anti-tumor activity in a subset of patients.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hepatology

HepatologyMedicine